Literature DB >> 11139479

The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.

O F Bueno1, L J De Windt, H W Lim, K M Tymitz, S A Witt, T R Kimball, J D Molkentin.   

Abstract

Mitogen-activated protein kinase (MAPK) signaling pathways are important regulators of cell growth, proliferation, and stress responsiveness. A family of dual-specificity MAP kinase phosphatases (MKPs) act as critical counteracting factors that directly regulate the magnitude and duration of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) activation. Here we show that constitutive expression of MKP-1 in cultured primary cardiomyocytes using adenovirus-mediated gene transfer blocked the activation of p38, JNK1/2, and ERK1/2 and prevented agonist-induced hypertrophy. Transgenic mice expressing physiological levels of MKP-1 in the heart showed (1) no activation of p38, JNK1/2, or ERK1/2; (2) diminished developmental myocardial growth; and (3) attenuated hypertrophy in response to aortic banding and catecholamine infusion. These results provide further evidence implicating MAPK signaling factors as obligate regulators of cardiac growth and hypertrophy and demonstrate the importance of dual-specificity phosphatases as counterbalancing regulatory factors in the heart.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11139479     DOI: 10.1161/01.res.88.1.88

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  50 in total

Review 1.  Mixed signals in heart failure: cancer rules.

Authors:  Masahiko Hoshijima; Kenneth R Chien
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1.

Authors:  Latronya T McCollum; Patricia E Gallagher; E Ann Tallant
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-02       Impact factor: 4.733

3.  Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase.

Authors:  Stacey L House; Brian E House; Betty Glascock; Thomas Kimball; Eyad Nusayr; Jo El J Schultz; Thomas Doetschman
Journal:  Mol Cell Pharmacol       Date:  2010

4.  Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.

Authors:  Yi Jin; Thomas J Calvert; Bernadette Chen; Louis G Chicoine; Mandar Joshi; John Anthony Bauer; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

Review 5.  Mitogen-activated protein kinases in heart development and diseases.

Authors:  Yibin Wang
Journal:  Circulation       Date:  2007-09-18       Impact factor: 29.690

6.  MicroRNA-200c modulates DUSP-1 expression in diabetes-induced cardiac hypertrophy.

Authors:  Gurinder Bir Singh; Satish K Raut; Sanskriti Khanna; Akhilesh Kumar; Saurabh Sharma; Rishikesh Prasad; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2016-09-30       Impact factor: 3.396

Review 7.  Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs).

Authors:  Ruijie Liu; Jeffery D Molkentin
Journal:  J Mol Cell Cardiol       Date:  2016-08-27       Impact factor: 5.000

8.  Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).

Authors:  Mark Rolfe; Laura E McLeod; Phillip F Pratt; Christopher G Proud
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

9.  Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.

Authors:  Beate Fiedler; Suzanne M Lohmann; Albert Smolenski; Stephan Linnemuller; Burkert Pieske; Frank Schroder; Jeffery D Molkentin; Helmut Drexler; Kai C Wollert
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

Review 10.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.